Travere Therapeutics Stock Performance
| TVTX Stock | USD 31.99 1.71 5.65% |
The entity has a beta of 1.33, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Travere Therapeutics will likely underperform. At this point, Travere Therapeutics has a negative expected return of -0.084%. Please make sure to validate Travere Therapeutics' skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Travere Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Travere Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Travere Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 58.2 M | |
| Total Cashflows From Investing Activities | 99.3 M |
Travere Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,516 in Travere Therapeutics on October 31, 2025 and sell it today you would lose (317.00) from holding Travere Therapeutics or give up 9.02% of portfolio value over 90 days. Travere Therapeutics is currently does not generate positive expected returns and assumes 3.7805% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Travere, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Travere Therapeutics Target Price Odds to finish over Current Price
The tendency of Travere Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 31.99 | 90 days | 31.99 | about 78.38 |
Based on a normal probability distribution, the odds of Travere Therapeutics to move above the current price in 90 days from now is about 78.38 (This Travere Therapeutics probability density function shows the probability of Travere Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.33 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Travere Therapeutics will likely underperform. Additionally Travere Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Travere Therapeutics Price Density |
| Price |
Predictive Modules for Travere Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Travere Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Travere Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Travere Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Travere Therapeutics is not an exception. The market had few large corrections towards the Travere Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Travere Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Travere Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.16 | |
β | Beta against Dow Jones | 1.33 | |
σ | Overall volatility | 2.93 | |
Ir | Information ratio | -0.04 |
Travere Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Travere Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Travere Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Travere Therapeutics generated a negative expected return over the last 90 days | |
| Travere Therapeutics has high historical volatility and very poor performance | |
| Travere Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 233.18 M. Net Loss for the year was (320.63 M) with profit before overhead, payroll, taxes, and interest of 215.28 M. | |
| Travere Therapeutics currently holds about 553.17 M in cash with (237.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Legend Biotech Corporation Sponsored ADR Given Consensus Recommendation of Moderate Buy by Brokerages |
Travere Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Travere Stock often depends not only on the future outlook of the current and potential Travere Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Travere Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 78.9 M | |
| Cash And Short Term Investments | 370.7 M |
Travere Therapeutics Fundamentals Growth
Travere Stock prices reflect investors' perceptions of the future prospects and financial health of Travere Therapeutics, and Travere Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Travere Stock performance.
| Return On Equity | -4.11 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.20) % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 2.76 B | |||
| Shares Outstanding | 89.47 M | |||
| Price To Book | 36.52 X | |||
| Price To Sales | 6.17 X | |||
| Revenue | 233.18 M | |||
| EBITDA | (265.77 M) | |||
| Cash And Equivalents | 553.17 M | |||
| Cash Per Share | 8.65 X | |||
| Total Debt | 401.58 M | |||
| Debt To Equity | 2.60 % | |||
| Book Value Per Share | 0.82 X | |||
| Cash Flow From Operations | (237.47 M) | |||
| Earnings Per Share | (1.03) X | |||
| Total Asset | 594.12 M | |||
| Retained Earnings | (1.45 B) | |||
About Travere Therapeutics Performance
Evaluating Travere Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Travere Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Travere Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Travere Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 310 people.Things to note about Travere Therapeutics performance evaluation
Checking the ongoing alerts about Travere Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Travere Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Travere Therapeutics generated a negative expected return over the last 90 days | |
| Travere Therapeutics has high historical volatility and very poor performance | |
| Travere Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 233.18 M. Net Loss for the year was (320.63 M) with profit before overhead, payroll, taxes, and interest of 215.28 M. | |
| Travere Therapeutics currently holds about 553.17 M in cash with (237.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Legend Biotech Corporation Sponsored ADR Given Consensus Recommendation of Moderate Buy by Brokerages |
- Analyzing Travere Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Travere Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Travere Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Travere Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Travere Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Travere Therapeutics' stock. These opinions can provide insight into Travere Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.